$VKTX (Viking Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 3.1%)

Graded daily on value F, growth D, profitability D, momentum C-, revisions C+. Sector-relative, identical for every user.

Recent discussion events

• [bullish] Investors compare VK2735 favorably to Lilly's tirzepatide, citing superior weight loss potential and cheap valuation amid obesity drug discussions. (5 posts)

Most active credible voices on $VKTX

• @pharmdca (Pharmdca) — 150 mentions · 109.8K followers
• @semodough (dough) — 109 mentions · 44.3K followers
• @aistocksavvy (Hardik Shah) — 21 mentions · 41.4K followers

Recent headlines featuring $VKTX

• 2026-09-27: Viking’s maintenance data keeps VK2735 in focus as analysts highlight 97% weight-loss retention
• 2026-09-24: Meta’s Muse reaches about 700,000 DAUs as shares jump over 30% in September
• 2026-09-23: Nasdaq-100 closes at record as SpaceX weight doubles to 2.82%
• 2026-09-22: Viking VK2735 maintenance data lifts shares premarket

Stock Ratings · Today Headlines · SpikePanel